BioInteractions launches TridAnt medical devices coating

BioInteractions, a UK biomaterial technology company, has launched TridAnt, a new coating technology for medical devices which represents a paradigm shift in infection prevention and protection against a broad range of pathogens.

TridAnt incorporates active and passive components to create a non-leaching, effective, safe and durable antimicrobial coating for medical devices and implants.

The World Health Organisation estimates that healthcare-associated infections (HCAI), especially those caused by antimicrobial-resistant pathogens, are the most frequently occurring adverse event in any healthcare system regardless of available resources.

Arjun Luthra, commercial director for BioInteractions, said: “Strict hygiene regimes and existing disinfectants have limited efficacy in reducing the risk of infection for prolonged periods of time. Our TridAnt solution offers a new way to combat infections more effectively, efficiently and for longer. Based on over three decades of dedicated research and trials, TridAnt is fully compliant with current medical device regulations, has been independently tested to international standards (ISO, EN, PAS) and proven to provide monoclonal protection which kills a broad spectrum of gram-positive & gram-negative bacteria as well as enveloped & non-enveloped viruses, including E.Coli, MRSA, Influenza, Norovirus and SARS-Cov-2. TridAnt is suitable for skin protection as well as most other surfaces including woven and non-woven fabrics including metals (nitinol) as well as polymers (polycarbonate & polyurethanes).”

The new antimicrobial technology is non-leaching and therefore completely safe to use in all environments and even for implants inside the human body. Its active components target microbes (prokaryotic cells) and has reduced risk to human cells unlike previous technologies. It is the first known medical device technology to kill enveloped as well as non-enveloped viruses and gram-positive as well as gram-negative bacteria which prevents the formation of biofilms for long-periods of time of up to 365 days (as well as safe enough to protect skin for up to 48 hours) without any noticeable reduction in efficacy.

In addition to creating a safe and efficient method to kill microbes long-term, the team behind TridAnt also focused on creating the best bioengineering method to bond the antimicrobial coating securely to the material of the different medical devices for their lifecycle. As a result, TridAnt-coated medical devices are protected with a highly effective and non-leaching shield for the entire lifetime of the device.

Dr Catriona Anderson, experienced NHS GP and specialist in treatment of microorganism and bacterial infections, said: “The prospect of a biocompatible technology which can enhance the function of medical devices through eliminating existing microbes and also preventing the formation of new colonies represents a paradigm shift in prevention and treatment of surgical infections. If the results of these lab tests translate into the real world and prolong the active lifecycle of medical devices it will have significant economic, health and social care impact.”

Overall, TridAnt significantly reduces the infection risk associated with medical procedures and actively reduces the contamination of pathogens within a patient.

BioInteractions will be exhibiting at Med-Tech Innovation Expo on 8-9 June at Stand B5 at the NEC, Birmingham. For more information, visit med-techexpo.com.